Chen, Shuchun
Yu, Seong-Jin
Li, Yazhou
Lecca, Daniela
Glotfelty, Elliot
Kim, Hee Kyung
Choi, Ho-Il
Hoffer, Barry J.
Greig, Nigel H.
Kim, Dong Seok
Wang, Yun
Article History
Received: 6 March 2018
Accepted: 13 June 2018
First Online: 16 July 2018
Change Date: 12 September 2018
Change Type: Correction
Change Details: A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
Competing Interests
: H.-K. Kim, D.-S. Kim and H.-I. Choi are employees of Peptron Inc. The Intramural Research Program of the National Institute on Aging, NIH, and Peptron Inc. have a Cooperative Research and Development Agreement to develop exendin-4 (exenatide) as a treatment strategy for neurodegenerative disorders for which NIA and Peptron Inc. hold patent rights via the work of H.-K. Kim, D.-S. Kim, H.I.-Choi and N.H. Greig (NIH: Greig N.H. <i>et al</i>., U.S. Patents 8,278,272 and 8,853,160 (issued); joint Peptron/NIH: Kim D.-S. <i>et al</i>., PCT/US17/57606 (pending)). N.H. Greig has assigned all patent rights to the NIH and US Government. All other authors declare no competing financial interests.